Endologix, Inc. (NASDAQ:ELGX) fell 1.8% on Friday . The stock traded as low as $6.22 and last traded at $6.52, 3,461 shares traded hands during trading. A decline of 99% from the average session volume of 337,461 shares. The stock had previously closed at $6.64.
Several research firms have recently weighed in on ELGX. ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Zacks Investment Research cut EXACT Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Finally, Stifel Nicolaus set a $7.00 price target on Endologix and gave the company a “hold” rating in a report on Monday, April 1st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. Endologix currently has a consensus rating of “Hold” and a consensus price target of $25.63.
The stock has a fifty day simple moving average of $7.28. The company has a market capitalization of $116.60 million, a P/E ratio of -0.93 and a beta of 0.38. The company has a debt-to-equity ratio of 11.12, a current ratio of 1.58 and a quick ratio of 0.90.
Endologix (NASDAQ:ELGX) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported ($1.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.56) by $0.44. Endologix had a negative return on equity of 173.52% and a negative net margin of 54.72%. The company had revenue of $35.61 million for the quarter, compared to analysts’ expectations of $34.18 million. On average, equities research analysts forecast that Endologix, Inc. will post -3.65 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. Deutsche Bank AG raised its position in shares of Endologix by 121.3% in the fourth quarter. Deutsche Bank AG now owns 433,335 shares of the medical instruments supplier’s stock worth $309,000 after acquiring an additional 237,555 shares during the period. Norges Bank acquired a new position in shares of Endologix in the fourth quarter worth about $545,000. Macquarie Group Ltd. acquired a new position in shares of Endologix in the fourth quarter worth about $46,000. Jane Street Group LLC raised its position in shares of Endologix by 54.6% in the fourth quarter. Jane Street Group LLC now owns 93,572 shares of the medical instruments supplier’s stock worth $67,000 after acquiring an additional 33,044 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its position in shares of Endologix by 17.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,941,830 shares of the medical instruments supplier’s stock worth $1,390,000 after acquiring an additional 286,366 shares during the period. 48.67% of the stock is currently owned by institutional investors.
About Endologix (NASDAQ:ELGX)
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
Featured Story: What is channel trading?
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.